Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline Review H1 2015


#307262

378pages

Global Markets Direct

$ 2000

In Stock

Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline Review H1 2015

Summary

Global Markets Directs Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline Review H1 2015 provides an overview of the Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancers therapeutic pipeline

This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action (MoA) route of administration (RoA) and molecule type along with latest updates and featured news and press releases It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3000 indications The report is built using data and information sourced from Global Markets Directs proprietary databases Company/University websites SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources put together by Global Markets Directs team Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information Additionally processes including live news & deals tracking browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes product description MoA and R&D brief licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer pipeline on the basis of target MoA route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information analysis and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Overview 11
Therapeutics Development 12
Pipeline Products for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Overview 12
Pipeline Products for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Comparative Analysis 13
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies 14
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 19
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Products under Development by Companies 23
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes 28
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development 29
AB Science 29
AbbVie Inc 30
Adamis Pharmaceuticals Corporation 31
Advaxis Inc 32
Ambrx Inc 33
Amgen Inc 34
Arrowhead Research Corporation 35
AstraZeneca Plc 36
ATLAB Pharma SAS 37
Bavarian Nordic A/S 38
Bellicum Pharmaceuticals Inc 39
BIND Therapeutics Inc 40
Boehringer Ingelheim GmbH 41
Bristol-Myers Squibb Company 42
Celgene Corporation 43
CellCentric Ltd 44
DexTech Medical AB 45
Eli Lilly and Company 46
Emergent BioSolutions Inc 47
F Hoffmann-La Roche Ltd 48
Genentech Inc 49
GenSpera Inc 50
GlaxoSmithKline Plc 51
GTx Inc 52
Johnson & Johnson 53
Karyopharm Therapeutics Inc 54
Medivation Inc 55
Millennium Pharmaceuticals Inc 56
NewLink Genetics Corporation 57
Novartis AG 58
Oncogenex Pharmaceuticals Inc 59
Oncolytics Biotech Inc 60
Onyx Pharmaceuticals Inc 61
Orion Oyj 62
Pfizer Inc 63
Progenics Pharmaceuticals Inc 64
Sanofi 65
Sotio as 66
Sun Pharma Advanced Research Company Ltd 67
Supratek Pharma Inc 68
Synta Pharmaceuticals Corp 69
Takeda Pharmaceutical Company Limited 70
Tokai Pharmaceuticals Inc 71
TRACON Pharmaceuticals Inc 72
Viralytics Ltd 73
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Therapeutics Assessment 74
Assessment by Monotherapy Products 74
Assessment by Target 75
Assessment by Mechanism of Action 79
Assessment by Route of Administration 82
Assessment by Molecule Type 84
Drug Profiles 86
abiraterone acetate - Drug Profile 86
ABS-001 - Drug Profile 89
Adipotide - Drug Profile 90
ADXS-PSA - Drug Profile 91
afuresertib hydrochloride - Drug Profile 93
apatorsen - Drug Profile 95
APC-200 - Drug Profile 97
APC-300 - Drug Profile 98
ASN-001 - Drug Profile 99
ATL-101 - Drug Profile 100
AZD-5312 - Drug Profile 102
AZD-5363 - Drug Profile 103
BI-836845 - Drug Profile 105
BMTP-11 - Drug Profile 107
BPX-201 - Drug Profile 108
cabazitaxel - Drug Profile 109
cabazitaxel - Drug Profile 111
carfilzomib - Drug Profile 112
CC-115 - Drug Profile 116
Cell Therapy to Target PSMA for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 117
CFG-920 - Drug Profile 118
crizotinib - Drug Profile 119
custirsen sodium - Drug Profile 123
CVA-21 - Drug Profile 127
Dendritic Cell Therapy to Target PSA PAP Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 131
docetaxel - Drug Profile 132
docetaxel - Drug Profile 134
DPV-001 - Drug Profile 135
emibetuzumab - Drug Profile 137
enzalutamide - Drug Profile 138
erismodegib - Drug Profile 141
ES-414 - Drug Profile 144
everolimus - Drug Profile 145
galeterone - Drug Profile 151
ganetespib - Drug Profile 153
GSK-2636771 - Drug Profile 157
GTx-758 - Drug Profile 158
idasanutlin - Drug Profile 160
indoximod - Drug Profile 162
ipilimumab - Drug Profile 164
JNJ-56021927 - Drug Profile 168
LY-3022855 - Drug Profile 170
LY-3023414 - Drug Profile 171
masitinib - Drug Profile 173
mipsagargin - Drug Profile 176
Monoclonal Antibody Drug Conjugate to Inhibit PSMA for GBM and CRPC - Drug Profile 178
MVI-816 - Drug Profile 179
navitoclax dihydrochloride - Drug Profile 181
ODM-201 - Drug Profile 183
ODM-204 - Drug Profile 185
olaparib - Drug Profile 186
olaratumab - Drug Profile 190
ONC-113B - Drug Profile 192
Osteodex - Drug Profile 193
pelareorep - Drug Profile 194
Protein for Prostate Cancer - Drug Profile 199
PSMA ADC - Drug Profile 200
RG-7450 - Drug Profile 202
rilimogene galvacirepvec - Drug Profile 203
rilotumumab - Drug Profile 206
sapanisertib - Drug Profile 208
selinexor - Drug Profile 210
Small Molecule to Antagonize Androgen Receptor for Prostate Cancer - Drug Profile 215
Small Molecules to Antagonize Androgen Receptor for Metastatic Castration Resistant Prostate Cancer - Drug Profile 216
Small Molecules to Inhibit Bromodomain for Prostate Cancer - Drug Profile 217
Small Molecules to Inhibit Deubiquitinase for Castrate Resistant Prostate Cancer - Drug Profile 218
stapuldencel-t - Drug Profile 219
TL-118 - Drug Profile 221
TRC-105 - Drug Profile 223
Vaccine for Prostate Cancer - Drug Profile 226
Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 229
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Recent Pipeline Updates 231
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Dormant Projects 356
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Discontinued Products 360
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Product Development Milestones 362
Featured News & Press Releases 362
Appendix 372
Methodology 372
Coverage 372
Secondary Research 372
Primary Research 372
Expert Panel Validation 372
Contact Us 372
Disclaimer 373

List of Tables
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer H1 2015 17
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Comparative Analysis H1 2015 18
Number of Products under Development by Companies H1 2015 20
Number of Products under Development by Companies H1 2015 (Contd1) 21
Number of Products under Development by Companies H1 2015 (Contd2) 22
Number of Products under Development by Companies H1 2015 (Contd3) 23
Number of Products under Investigation by Universities/Institutes H1 2015 24
Comparative Analysis by Late Stage Development H1 2015 25
Comparative Analysis by Clinical Stage Development H1 2015 26
Comparative Analysis by Early Stage Development H1 2015 27
Products under Development by Companies H1 2015 28
Products under Development by Companies H1 2015 (Contd1) 29
Products under Development by Companies H1 2015 (Contd2) 30
Products under Development by Companies H1 2015 (Contd3) 31
Products under Development by Companies H1 2015 (Contd4) 32
Products under Investigation by Universities/Institutes H1 2015 33
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by AB Science H1 2015 34
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by AbbVie Inc H1 2015 35
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation H1 2015 36
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Advaxis Inc H1 2015 37
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Ambrx Inc H1 2015 38
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Amgen Inc H1 2015 39
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Arrowhead Research Corporation H1 2015 40
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca Plc H1 2015 41
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by ATLAB Pharma SAS H1 2015 42
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S H1 2015 43
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Bellicum Pharmaceuticals Inc H1 2015 44
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by BIND Therapeutics Inc H1 2015 45
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH H1 2015 46
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Bristol-Myers Squibb Company H1 2015 47
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Celgene Corporation H1 2015 48
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by CellCentric Ltd H1 2015 49
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB H1 2015 50
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company H1 2015 51
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Emergent BioSolutions Inc H1 2015 52
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by F Hoffmann-La Roche Ltd H1 2015 53
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Genentech Inc H1 2015 54
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by GenSpera Inc H1 2015 55
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by GlaxoSmithKline Plc H1 2015 56
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by GTx Inc H1 2015 57
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson H1 2015 58
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Karyopharm Therapeutics Inc H1 2015 59
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Medivation Inc H1 2015 60
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals Inc H1 2015 61
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation H1 2015 62
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG H1 2015 63
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals Inc H1 2015 64
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Oncolytics Biotech Inc H1 2015 65
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Onyx Pharmaceuticals Inc H1 2015 66
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Orion Oyj H1 2015 67
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Pfizer Inc H1 2015 68
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Progenics Pharmaceuticals Inc H1 2015 69
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Sanofi H1 2015 70
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Sotio as H1 2015 71
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd H1 2015 72
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Supratek Pharma Inc H1 2015 73
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Synta Pharmaceuticals Corp H1 2015 74
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Limited H1 2015 75
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Tokai Pharmaceuticals Inc H1 2015 76
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by TRACON Pharmaceuticals Inc H1 2015 77
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Pipeline by Viralytics Ltd H1 2015 78
Assessment by Monotherapy Products H1 2015 79
Number of Products by Stage and Target H1 2015 81
Number of Products by Stage and Mechanism of Action H1 2015 85
Number of Products by Stage and Route of Administration H1 2015 88
Number of Products by Stage and Molecule Type H1 2015 90
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Therapeutics - Recent Pipeline Updates H1 2015 236
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Dormant Projects H1 2015 361
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Dormant Projects (Contd1) H1 2015 362
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Dormant Projects (Contd2) H1 2015 363
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Dormant Projects (Contd3) H1 2015 364
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Discontinued Products H1 2015 365
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Discontinued Products (Contd1) H1 2015 366

List of Figures
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer H1 2015 17
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer - Comparative Analysis H1 2015 18
Number of Products under Development by Companies H1 2015 19
Number of Products under Investigation by Universities/Institutes H1 2015 24
Comparative Analysis by Clinical Stage Development H1 2015 26
Comparative Analysis by Early Stage Products H1 2015 27
Assessment by Monotherapy Products H1 2015 79
Number of Products by Top 10 Targets H1 2015 80
Number of Products by Stage and Top 10 Targets H1 2015 80
Number of Products by Top 10 Mechanism of Actions H1 2015 84
Number of Products by Stage and Top 10 Mechanism of Actions H1 2015 84
Number of Products by Top 10 Routes of Administration H1 2015 87
Number of Products by Stage and Top 10 Routes of Administration H1 2015 87
Number of Products by Top 10 Molecule Types H1 2015 89
Number of Products by Stage and Top 10 Molecule Types H1 2015 89